Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach
Menée en Australie à partir de données d'incidence des cancers et de mortalité sur la période 1982-2012, cette étude évalue la validité d'une nouvelle méthode, basée sur le risque de décès tout au long de la vie, pour estimer le surdiagnostic de cancer de la prostate lié au dépistage par dosage sérique du PSA
Objectives : To quantify the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.
Design : Modelling and validation of the lifetime risk method using publicly available population data.
Setting : Opportunistic screening for prostate cancer in the Australian population.
Participants : Australian male population (1982–2012).
Interventions : Prostate-specific antigen testing for prostate cancer screening.
Primary and secondary : outcome measures Primary: lifetime risk of overdiagnosis in 2012 (excess lifetime cancer risk adjusted for changing competing mortality); Secondary: lifetime risk of prostate cancer diagnosis (unadjusted and adjusted for competing mortality); Excess lifetime risk of prostate cancer diagnosis (for all years subsequent to 1982).
Results : The lifetime risk of being diagnosed with prostate cancer increased from 6.1% in 1982 (1 in 17) to 19.6% in 2012 (1 in 5). Using 2012 competing mortality rates, the lifetime risk in 1982 was 11.5% (95% CI 11.0% to 12.0%). The excess lifetime risk of prostate cancer in 2012 (adjusted for changing competing mortality) was 8.2% (95% CI 7.6% to 8.7%) (1 in 13). This corresponds to 41% of prostate cancers being overdiagnosed.
Conclusions : Our estimated rate of overdiagnosis is in agreement with estimates using other methods. This method may be used without the need to adjust for lead times. If annual (cross-sectional) data are used, then it may give valid estimates of overdiagnosis once screening has been established long enough for the benefits from the early detection of non-overdiagnosed cancer at a younger age to be realised in older age groups.
BMJ Open , article en libre accès, 2018